Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment

Regulatory Toxicology and Pharmacology

Volumn 66, Issue 1, 2013, Pages 116-129

  Bette Meek, M E ^a   Barton, Hugh A ^b   Bessems, Jos G ^c   Lipscomb, John C ^d   Krishnan, Kannan ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b PFIZER INC   (United States)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

2 Butoxyethanol; Physiologically based pharmacokinetic (PBPK) modeling; Risk assessment

Indexed keywords

2 BUTOXYETHANOL;

ARTICLE; BLOOD TOXICITY; CONCENTRATION RESPONSE; HUMAN; INHALATION; METABOLISM; NONHUMAN; PEER REVIEW; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; TOXICITY TESTING; TOXICOKINETICS; UNCERTAINTY;

ANIMALS; ETHYLENE GLYCOLS; HAZARDOUS SUBSTANCES; HUMANS; INTERNATIONAL COOPERATION; MODELS, BIOLOGICAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 84876494689     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.03.005     Document Type: Article

References (49)

1. Andersen M.E. Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol. Lett. 2003, 138:9-27.
2. Barton H.A., Chiu W.A., Setzer R.W., Andersen M.E., Bailer A.J., Bois F.Y., Dewoskin R.S., Hays S., Johanson G., Jones N., Loizou G., Macphail R.C., Portier C.J., Spendiff M., Tan Y.M. Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: state of the science and needs for research and implementation. Toxicol. Sci. 2007, 99:395-402.
3. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., Willcocks D., Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 2006, 36:781-792.
4. Boobis A.R., Doe J.E., Heinrich-Hirsch B., Meek M.E., Munn S., Ruchirawat M., Schlatter J., Seed J., Vickers C. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 2008, 38:87-96.
5. Chiu W.A., Barton H.A., Dewoskin R.S., Schlosser P., Thompson C.M., Sonawane B., Lipscomb J.C., Krishnan K. Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J. Appl. Toxicol. 2007, 27:218-237.
6. Clark L.H., Setzer R.W., Barton H.A. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 2004, 24:1697-1717.
7. Clewell H.J., Andersen M.E. Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1985, 1:111-131.
8. Clewell H.J., Andersen M.E. Dose, species, and route extrapolation using physiologically based pharmacokinetic models. Pharmacokinetics in Risk Assessment: Drinking Water and Health 1987, vol. 8:159-184. National Academy Press, Washington, DC.
9. Clewell H.J., Andersen M.E., Barton H.A. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect. 2002, 110:85-93.
10. Corley R.A., Markham D.A., Banks C., Delorme P., Masterman A., Houle J.M. Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. Fundam. Appl. Toxicol. 1997, 39:120-130.
11. Corley R.A., Bormett G.A., Ghanayem B.I. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol. Appl. Pharmacol. 1994, 129:61-79.
12. Dedrick R.L., Forrester D.D., Ho D.H.W. In vitro-in vivo correlation of drug metabolism: deamination of 1-β-d-arabinosyl cytosine. Biochem. Pharmacol. 1972, 21:1-16.
13. Environment Canada & Health Canada, 2002. Canadian Environmental Protection Act, 1999: Priority Substances List Assessment Report: 2-butoxyethanol. Ottawa, Ontario, Government of Canada. Available at: http://www.198.103.98.185/ewh-semt/pubs/contaminants/psl2-lsp2/2_butoxyethanol/index-eng.php.
14. Environment Canada & Health Canada, 2003. Canadian Environmental Protection Act, 1999: Priority Substances List Health Assessment Supporting Documentation, 2-butoxyethanol. April 2003. (Available by request from Health and Environment Canada).
15. Fiserova-Bergerova V Modeling of Inhalation Exposure to Vapors: Uptake Distribution and Elimination 1983, vol. 2:108-130. CRC Press, Boca Raton, FL.
16. Gentry, P.R., Covington, T.R., Clewell, H.J., Andersen, M.E., 2004. Good Modeling Practices for Pharmacokinetic Models in Chemical Risk Assessment. Report prepared under contract to the Environmental Health Directorate of Health Canada, March, 2004.
17. Ghanayem B.I., Blair P.C., Thompson M.B., Maronpot R.R., Matthews H.B. Effect of age on the toxicity and metabolism of ethylene glycol monobutyl ether (2-butoxyethanol) in rats. Toxicol. Appl. Pharmacol. 1987, 91:222-234.
18. Ghanayem B.I., Burka L.T., Sanders J.M., Matthews H.B. Metabolism and disposition of ethylene glycol monobutyl ether (2-butoxyethanol) in rats. Drug Metab. Dispos. 1987, 15:478-484.
19. Ghanayem B.I. Metabolic and cellular basis of 2-butoxyethanol-induced hemolytic anemia in rats and assessment of human risk in vitro. Biochem. Pharmacol. 1989, 38:1679-1684.
20. Ghanayem B.I., Sanders J.M., Clark A.M., Bailer J., Matthews H.B. Effects of dose, age, inhibition of metabolism and elimination on the toxicokinetics of 2-butoxyethanol and its metabolites. J. Pharmacol. Exp. Ther. 1990, 253:136-143.
21. International Programme on Chemical Safety (IPCS), 1999. Principles for the assessment of risks to human health from exposure to chemicals. Environmental health criteria 210, World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. Available at: http://www.inchem.org/documents/ehc/ehc/ehc210.htm.
22. International Programme on Chemical Safety (IPCS), 2004. IPCS risk assessment terminology. Harmonization project document no. 1. World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. Available at: http://www.who.int/ipcs/methods/harmonization/areas/ipcsterminologyparts1and2.pdf.
23. International Programme on Chemical Safety (IPCS), 2005a. Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentration-response assessment. Harmonization project document no. 2. World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. Available at: http://www.whqlibdoc.who.int/publications/2005/9241546786_eng.pdf.
24. International Programme on Chemical Safety (IPCS), 2005b. Principles of characterizing and applying human exposure models. Harmonization project document no. 3. World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. Available at: http://www.whqlibdoc.who.int/publications/2005/9241563117_eng.pdf.
25. International Programme on Chemical Safety (IPCS), 2008. Part 1. Guidance document on characterizing and communicating uncertainty in exposure assessment. In: Uncertainty and Data Quality in Exposure Assessment. Harmonization Project Document No. 6. World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. http://www.who.int/ipcs/publications/methods/harmonization/exposure_assessment.pdf.
26. International Programme on Chemical Safety (IPCS), 2010. Characterization and application of physiologically based pharmacokinetic models in risk assessment, World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. http://www.who.int/ipcs/methods/harmonization/areas/pbpk_models.pdf.
27. Johanson G., Kronborg H., Naslund P.H., Byfalt Nordqvist M. Toxicokinetics of inhaled 2-butoxyethanol (ethylene glycol monobutyl ether) in man. Scand. J. Work Environ. Health 1986, 12:594-602.
28. Johanson G., Boman A. Percutaneous absorption of 2-butoxy-ethanol vapour in human subjects. Br. J. Ind. Med. 1991, 48:788-792.
29. Johanson G., Johnsson S. Gas chromatographic determination of butoxyacetic acid in human blood after exposure to 2-butoxyethanol. Arch. Toxicol. 1991, 65:433-435.
30. Krishnan K., Andersen M.E. Physiologically-based pharmacokinetic and toxicokinetic modeling. Principles and Methods in Toxicology 2007, 232-291. Taylor and Francis, New York, NY. A.W. Hayes (Ed.).
31. Lee K.M., Dill J.A., Chou B.J., Roycroft J.H. Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol. Toxicol. Appl. Pharmacol. 1998, 153:211-226.
32. Toxicokinetics and Risk Assessment 2007, 361. Informa Healthcare, New York, NY. J.C. Lipscomb, E.V. Ohanian (Eds.).
33. Loizou G., Spendiff M., Barton H.A., Bessems J., Bois F.Y., d'Yvoire M.B., Buist H., Clewell H.J., Meek B., Gundert-Remy U., Goerlitz G., Schmitt W. Development of good modeling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul. Toxicol. Pharmacol. 2008, 50:400-441.
34. Medinsky M.A., Singh G., Bechtold W.E., Bond J.A., Sabourin P.J., Birnbaum L.S., Henderson R.F. Disposition of three glycol ethers administered in drinking water to male F344/N rats. Toxicol. Appl. Pharmacol. 1990, 102:443-455.
35. Meek M.E. Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ. Mol. Mutagen 2008, 49:110-116.
36. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
37. Meek M.E., Klaunig J.E. Proposed mode of action of benzene-induced leukemia: interpreting available data and identifying critical data gaps for risk assessment. Chem. Biol. Interact. 2010, 184:279-285.
38. National Toxicology Program (NTP), 1998. Toxicology and carcinogenesis studies of 2-butoxyethanol (CAS No. 111-76-2) in F344/N rats and B6C3F1 mice (inhalation studies). Draft technical report (NTP TR 484). National Institutes of Health, U.S Department of Health and Human Services, Research Triangle Park, North Carolina. Available at: http://www.ntp.niehs.nih.gov/?objectid=070AC403-B110-CA79-3A23AF79DE7B752A.
39. NRC Pharmacokinetics in risk assessment: drinking water and health. Prepared by the Safe Drinking Water Committee, National Research Council 1987, vol. 8. National Academy Press, Washington, DC.
40. Ramsey J.C., Andersen M.E. A physiological model for the inhalation pharmacokinetics of inhaled styrene monomer in rats and humans. Toxicol. Appl. Pharmacol. 1984, 73:159-175.
41. Physiologically Based Pharmacokinetic Modeling: Science and Application 2005, 420. John Wiley & Sons, Hoboken, NJ. M.B. Reddy, R.S.H. Yang, H.J. Clewell, M.E. Andersen (Eds.).
42. Sabourin P.J., Medinsky M.A., Birnbaum L.S., Griffith W.C., Henderson R.F. Effect of exposure concentration on the disposition of inhaled butoxyethanol by F344 rats. Toxicol. Appl. Pharmacol. 1992, 114:232-238.
43. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 2001, 34:46-52.
44. Seed J., Carney E., Corley E.R., Crofton K., DeSesso J., Foster P., Kavlock R., Kimmel G., Klaunig J., Meek E., Preston J., Slikker W., Tabacova S., Williams G., Wiltse J., Zoeller R.T., Fenner-Crisp P., Patton D.E. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 2005, 35(2005):663-672.
45. Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch. Int. Pharmacodyn. Thér. 1937, 57:205-225.
46. Teorell T. Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration. Arch. Int. Pharmacodyn. Thér. 1937, 57:226-240.
47. Thompson C.M., Johns D.O., Sonawane B., Barton H.A., Hattis D., Tardif R., Krishnan K. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J. Toxicol. Environ. Health B Crit. Rev. 2009, 12:1-24.
48. U.S. Environmental Protection Agency (U.S. EPA), 2006. Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment. EPA/600/R-05/043A. National Center for Environmental Assessment. Available at:http://www.cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=157668.
49. Zhao P., Rowland M., Huang S.M. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 2012, 92:17-20. 10.1038/clpt.2012.68.